Popular Articles

Cardiovascular Medication Costs In Canada Double
The number of prescriptions in Canada for cardiovascular medications has been increasing over the past decade, with a 200% increase in costs, found a new study in CMAJ (Canadian Medical Association Journal). In 2006, total costs of cardiovascular medications exceeded $5 billion, with statins accounting for almost 40% of the expenditure.
pharmacy online Dentisti fiume
Does Synthetic Biology Need Synthesized Ethics?
The emerging field of synthetic biology draws on a variety of technologies, including genetic engineering and nanotechnology, to engineer biological systems to perform novel tasks. As the science and its applications develop, instead of creating a "new kind" of ethics for each new techno-scientific arena, a comprehensive approach is needed to address ethical and social issues of emerging technologies as a whole, according to a report by Erik Parens, Josephine Johnston, and Jacob Moses of The Hastings Center. Synthetic biology promises significant advances in areas such as biofuels, specialty chemicals, agriculture, and medicine but also poses potential risks.
News of the day
Self-Regulation In Alcohol Advertising Not Working, As Ads Target Younger Drinkers
Addiction scientists are calling for tighter regulation of alcohol advertising, as new research shows that self-regulation by the alcohol industry does not protect impressionable children and youth from exposure.
Endocrinology

Significant Milestone Marks The Beginning Of FDA-Authorized Breast Cancer Trial

Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell therapy. QI is currently sponsoring and conducting an FDA-authorized Phase I/II clinical trial testing the safety and efficacy of its immunotherapy on 27 Stage IV breast cancer patients who have failed conventional therapy. According to Mr. Chuck Broes, CEO of QI, "This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome." The clinical trials involve the use of dendritic cell therapy using the oncofetal antigen ("OFA"), or iLRP -- immature Laminin Receptor Protein, as a cancer antigen (a protein found on cancer cells that can be targeted by the body"s own immune system) found in many tumor cell lines or fetal tissue, but absent on normal, healthy tissue. QI believes that the OFA antigen can serve as a unique, valuable and promising antigen for individualized breast cancer immunotherapy. Centered in Mobile, AL, QI"s clinical trial is designed around the use of QI"s proprietary dendritic cell therapy, which employs OFA to recruit the patient"s own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient"s own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient"s T-cells will locate the OFA found on the patient"s cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease. About Quantum Immunologics Quantum Immunologics, Inc. ("QI") is a research-driven biotechnology company that is pioneering discoveries in immunotherapy science. QI is dedicated to the research, development and production of technologies that focus on the treatments and diagnoses of cancer and other diseases related to the immune system. Leveraging an expansive pipeline of biopharmaceutical innovations, QI remains committed to advancing medicine with the ultimate goal of dramatically improving lives. Quantum Immunologics, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):